Correction: Glycemic Control in Type 2 Diabetes. Ann Intern Med. 2009;151:144. doi: 10.7326/0003-4819-151-2-200907210-00020
Download citation file:
Published: Ann Intern Med. 2009;151(2):144.
In the recent article on glycemic control in type 2 diabetes by Montori and Fernández-Balsells (1), the figure contained several incorrect numbers of patients in the intensive glycemic control (IGC) and conventional glycemic control (CGC) groups. The ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) study had 498 all-cause mortality events in the IGC group. The VADT (Veterans Affairs Diabetes Trial) had 40 and 33 cardiovascular mortality events in the IGC group and CGC group, respectively. For neuropathy, the VADT had 202 events in the ICG group and 218 events in the CGC group, and the correct relative risk is 0.93 (95% CI, 0.79 to 1.10). The correct relative risks for severe hypoglycemia in VADT and ADVANCE are 2.74 (CI, 1.80 to 4.17) and 1.85 (1.42 to 2.42), respectively. Denominators in the ICG and CGC groups for each study are 5128 and 5123 for ACCORD (Action to Control Cardiovascular Risk in Diabetes), 892 and 899 for VADT, 5571 and 5569 for ADVANCE, 2729 and 1138 for UKPDS(a) (United Kingdom Prospective Diabetes Study), 342 and 411 for UKPDS(b), and 1293 and 411 for UKPDS(c). Please note that these errors do not affect the article's conclusions. The online version of the figure has been corrected.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only